A Comprehensive Monograph on Chlorpheniramine (DB01114): From Classic Antihistamine to Modern Pharmacological Probe

1.0 Executive Summary

1.1 Overview of Chlorpheniramine

Chlorpheniramine, also known as chlorphenamine, is a small molecule drug belonging to the alkylamine class of first-generation antihistamines.[1] Patented in 1948 and introduced into widespread clinical use in the early 1950s, it represents one of the most enduring and widely utilized agents for the symptomatic management of allergic conditions.[1] For over seven decades, it has been a mainstay in both prescription and over-the-counter (OTC) pharmacotherapy, valued for its efficacy in alleviating symptoms of allergic rhinitis (hay fever), urticaria, and the common cold.[1] Its longevity in the market is a testament to its established effectiveness, though this is counterbalanced by a complex pharmacological profile and a significant burden of side effects that have been increasingly scrutinized under modern pharmacovigilance standards.

1.2 Key Pharmacological Characteristics and Clinical Profile

The primary therapeutic action of chlorpheniramine stems from its activity as a potent inverse agonist of the histamine H1 receptor.[1] By competitively binding to these receptors on effector cells, it blocks the actions of endogenous histamine, thereby mitigating the cascade of symptoms associated with type I hypersensitivity reactions.[6] However, its pharmacological activity is not confined to the histaminergic system. As a first-generation agent, chlorpheniramine is lipophilic and readily crosses the blood-brain barrier, a characteristic that is responsible for its prominent sedative effects.[7] Furthermore, it exhibits clinically relevant secondary activities, including weak antagonism of muscarinic acetylcholine receptors and potent inhibition of serotonin reuptake.[1] These off-target effects contribute significantly to its side effect profile, including anticholinergic symptoms like dry mouth and urinary retention, and create a potential for numerous drug interactions.

1.3 Summary of Therapeutic Uses and Safety Considerations

Chlorpheniramine is indicated for the symptomatic relief of sneezing, rhinorrhea, itchy and watery eyes, and pruritus associated with allergic rhinitis and other allergic states.[4] It is a ubiquitous component of multi-symptom OTC cold and flu preparations, where it is often combined with analgesics, decongestants, and antitussives.[10] Despite its efficacy, its use is governed by important safety considerations. The most common adverse effects are sedation and anticholinergic symptoms, which pose significant risks, particularly for older adults and individuals operating machinery.[1] Its use in geriatric populations is associated with an increased risk of confusion, falls, and has been linked to a higher cumulative risk of dementia.[1] In pediatrics, its use is contraindicated or strongly cautioned against in young children due to the risk of serious adverse events, including paradoxical excitation and respiratory depression.[6] The complex pharmacokinetic profile, characterized by a long elimination half-life despite a short duration of action, leads to drug accumulation and exacerbates these risks with repeated dosing.

2.0 Chemical Identity and Physicochemical Properties

2.1 Nomenclature and Identification Codes

Chlorpheniramine is a well-characterized small molecule drug identified by a variety of chemical names and database identifiers that ensure its unambiguous recognition in scientific, clinical, and regulatory contexts.[1] The most common non-proprietary names are chlorpheniramine (used predominantly in North America) and chlorphenamine (used in the United Kingdom and other regions).[1] It is chemically classified as a tertiary amino compound, a member of the monochlorobenzene and pyridine families, and belongs to the alkylamine series of antihistamines.[1] The drug is most frequently formulated and administered as a salt, chlorpheniramine maleate, which has its own distinct identifiers.[15] A comprehensive list of its key identification codes is provided in Table 2.1.

Table 2.1: Drug Identification Codes for Chlorpheniramine

Identifier Type	Value	Source(s)
DrugBank ID	DB01114	1
CAS Number (Free Base)	132-22-9	17
CAS Number (Maleate Salt)	113-92-8	15
PubChem CID	2725	1
UNII (Unique Ingredient Identifier)	3U6IO1965U	1
IUPHAR/BPS ID	1210	1
KEGG Drug ID	D07398	1
ChEBI ID	CHEBI:52010	1
ChEMBL ID	ChEMBL505	1
ATC Codes	R06AB02, R06AB04	10
ECHA InfoCard	100.004.596	1

2.2 Molecular Structure and Stereochemistry

The chemical formula for chlorpheniramine is C16​H19​ClN2​.[1] Its systematic IUPAC name is 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine.[5] This structure is precisely defined by standard chemical notations, including its SMILES string,

CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2, and its InChIKey, SOYKEARSMXGVTM-UHFFFAOYSA-N.[5]

A critical aspect of chlorpheniramine's molecular identity is its stereochemistry. The molecule possesses a chiral center at the carbon atom bonded to the chlorophenyl and pyridyl rings. Consequently, it exists as a pair of non-superimposable mirror-image molecules known as enantiomers.[1] In nearly all pharmaceutical preparations, chlorpheniramine is supplied as a racemic mixture, meaning it contains an equal 50:50 ratio of its two enantiomers: the dextrorotatory ((+)- or d-) form and the levorotatory ((-)- or l-) form.[1]

The pharmacological significance of this stereoisomerism is profound. The vast majority of the desired antihistaminic activity—the antagonism of the H1 receptor—resides almost exclusively in the dextrorotatory stereoisomer, which is also available as a separate drug named dexchlorpheniramine.[1] Studies have demonstrated that the d-isomer is substantially more potent, with some reports suggesting it is up to 100 times more active than the l-isomer at the H1 receptor.[20] The levorotatory enantiomer, levchlorpheniramine, is largely inactive at this primary target.[1] This disparity means that when a patient takes a standard 4 mg dose of racemic chlorpheniramine, they are effectively receiving only 2 mg of the therapeutically active compound. The remaining 2 mg of the l-isomer can be considered an "isomeric ballast"—an impurity that contributes little to the therapeutic effect but may still contribute to the drug's overall metabolic load or off-target effects. The continued widespread use of the racemate, rather than the purified active enantiomer, is largely a historical artifact. The drug was developed and commercialized before chiral separation techniques became routine and economically viable in pharmaceutical manufacturing. The established market presence and low cost of the racemic mixture have allowed it to persist, even though a more targeted therapeutic agent in the form of dexchlorpheniramine exists.

2.3 Physical and Chemical Properties

The physicochemical properties of chlorpheniramine and its maleate salt dictate its behavior in biological systems and its formulation into various dosage forms. The free base form of chlorpheniramine is described as an oily liquid.[5] However, it is almost universally formulated as chlorpheniramine maleate, a white, odorless crystalline solid or powder with a bitter taste.[16] This salt form enhances stability and improves water solubility, which is crucial for oral dosage forms. An aqueous solution of the maleate salt is slightly acidic, with a pH of 4-5 for a 1-2% solution.[16] The maleate salt is known to be sensitive to light, necessitating appropriate storage conditions.[5] Key physicochemical data are summarized in Table 2.2.

Table 2.2: Physicochemical Properties of Chlorpheniramine

Property	Value	Source(s)
Molar Mass	274.79 g·mol⁻¹ (free base) 390.86 g·mol⁻¹ (maleate salt)	1
Physical Description	Oily liquid (free base) White crystalline solid (maleate salt)	5
Melting Point	130–135 °C (maleate salt)	5
Boiling Point	142 °C at 1.0 mmHg (free base)	5
Solubility (Maleate salt, 25 °C)	Water: 160 mg/mL Ethanol: 330 mg/mL Chloroform: 240 mg/mL	5
Partition Coefficient (LogP)	3.38	5
Dissociation Constant (pKa)	9.13–9.26	5

The LogP value of 3.38 indicates that chlorpheniramine is moderately lipophilic, which facilitates its passage across biological membranes, including the blood-brain barrier—a key factor in its sedative properties.[5] Its pKa of approximately 9.2 indicates that it is a weak base and will be predominantly ionized (protonated) at physiological pH in the stomach and blood, which influences its absorption and distribution characteristics.[5]

3.0 Pharmacology

3.1 Pharmacodynamics: Mechanism of Action and Receptor Binding Profile

The pharmacodynamic profile of chlorpheniramine is complex, characterized by a primary, high-affinity interaction with the histamine H1 receptor, supplemented by several secondary activities at other neurochemical targets that contribute to both its therapeutic utility and its adverse effect profile.

3.1.1 Primary Activity: Histamine H1 Receptor Inverse Agonism

The principal mechanism of action of chlorpheniramine is its function as a competitive binder at histamine H1 receptors.[1] During an allergic reaction, histamine is released from mast cells and basophils, binding to H1 receptors on various tissues. This binding initiates a cascade of effects including vasodilation, increased capillary permeability (leading to edema and swelling), smooth muscle contraction (in the bronchi), and stimulation of sensory nerve endings (causing itching and pain).[3] Chlorpheniramine competitively blocks histamine from accessing these receptor sites, thereby preventing or reversing these symptoms.[6]

More precisely, chlorpheniramine is not merely a neutral antagonist but a potent inverse agonist of the H1 receptor.[1] A neutral antagonist simply blocks an agonist from binding, whereas an inverse agonist binds to the receptor and actively reduces its basal (constitutive) activity, even in the absence of histamine. This property may contribute to its high potency. Its affinity for the H1 receptor is strong, as evidenced by reported dissociation constants (

Kd​) of 15 nM and half-maximal inhibitory concentrations (IC50​) as low as 12 nM.[1]

This interaction is highly stereoselective. Studies measuring the inhibitory constant (Ki​) at the human cloned H1 receptor found values of 2.67 to 4.81 nM for the active dextrorotatory enantiomer (dexchlorpheniramine), while the levorotatory enantiomer had Ki​ values of 211 to 361 nM.[1] This difference of nearly two orders of magnitude confirms that dexchlorpheniramine is the pharmacologically active component responsible for the drug's antihistaminic effects.

3.1.2 Secondary Activities: Anticholinergic and Serotonergic Effects

Beyond its primary target, chlorpheniramine interacts with other receptor systems, contributing to its classification as a pharmacologically "dirty drug." These off-target activities are clinically significant.

• Anticholinergic Activity: Chlorpheniramine is widely described as possessing weak anticholinergic properties, acting as an antagonist at muscarinic acetylcholine receptors.[1] This activity is responsible for a constellation of common side effects, including dry mouth, nose, and throat; blurred vision; constipation; and urinary retention.[1]
• Serotonergic Activity: A less commonly appreciated but highly potent action of chlorpheniramine is its function as a serotonin reuptake inhibitor (SRI).[5] It binds to the serotonin transporter (SERT) with a Kd​ of 15.2 nM.[1] This affinity is remarkably high, on par with its affinity for the H1 receptor. In contrast, its affinity for the norepinephrine transporter (NET) and dopamine transporter (DAT) is very weak, with Kd​ values of 1,440 nM and 1,060 nM, respectively, indicating a selective action on the serotonergic system among monoamine transporters.[1] This SRI activity may underlie anecdotal reports of antidepressant properties and is the basis for its strong contraindication with monoamine oxidase inhibitors (MAOIs).[15]

An interesting contradiction emerges from this profile. Clinically, chlorpheniramine is rated by experts as a "high burden" anticholinergic drug, and its cumulative use is linked to cognitive decline and dementia in the elderly.[1] This clinical observation, however, is inconsistent with

in vitro binding data. Direct binding assays on human brain tissue report a Kd​ value of 1,300 nM for dexchlorpheniramine at muscarinic receptors, and other studies report even weaker affinities (Ki​ values of 20–30 µM).[1] This affinity is nearly 100-fold weaker than its affinity for the H1 receptor. This discrepancy suggests that the clinically significant anticholinergic effects are not a simple consequence of high-affinity receptor blockade. The observed burden may instead result from a combination of factors: the drug's high lipophilicity allows it to achieve substantial concentrations in the central nervous system, where even weak off-target binding can become physiologically relevant; its active metabolites may possess a different, more potent anticholinergic profile than the parent compound; or its potent blockade of H1 receptors within the brain may indirectly disrupt cholinergic neurotransmission pathways, producing an anticholinergic effect through network-level interactions rather than direct receptor antagonism. This highlights a crucial gap between simplified

in vitro pharmacology and the complex, integrated physiology of the human body.

3.2 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of chlorpheniramine explains its onset and duration of action, dosing requirements, and potential for accumulation and drug interactions.

3.2.1 Absorption and Bioavailability

Following oral administration, chlorpheniramine is well absorbed from the gastrointestinal tract.[3] The onset of therapeutic effects is typically observed within two hours.[1] Peak plasma concentrations (

Tmax​) are generally reached between 2 and 6 hours after a single oral dose.[3] However, the drug is subject to extensive first-pass metabolism in both the gut wall and the liver.[3] This presystemic elimination significantly reduces the amount of active drug that reaches systemic circulation, resulting in a low and highly variable oral bioavailability, reported to be in the range of 25% to 50%.[3] The presence of food in the stomach may delay the rate of absorption but does not appear to affect the overall extent of bioavailability.[3]

3.2.2 Distribution

Once in the bloodstream, chlorpheniramine is widely distributed throughout the body. It is approximately 70-72% bound to plasma proteins.[1] Its lipophilic nature facilitates extensive tissue uptake, which is reflected in its large apparent volume of distribution (

Vd​), averaging 2.5–3.2 L/kg in adults and up to 3.8 L/kg in children.[26] This large

Vd​ indicates that the drug concentrates in tissues outside of the plasma, with notable distribution to the liver, lungs, kidneys, and, critically, the brain.[3] Its ability to readily cross the blood-brain barrier is a defining feature of first-generation antihistamines and is the primary reason for its central nervous system effects, such as sedation.

3.2.3 Metabolism

Chlorpheniramine undergoes extensive hepatic metabolism, primarily mediated by the cytochrome P450 (CYP) enzyme system.[3] The principal enzyme responsible for its metabolism is CYP2D6.[1] The metabolic process involves sequential N-demethylation to form the primary metabolites, desmethylchlorpheniramine and didesmethylchlorpheniramine, which are then further processed before excretion.[3]

The metabolism of chlorpheniramine is stereoselective. The more pharmacologically active (S)-(+)-enantiomer is cleared from the body more slowly than the less active (R)-(-)-enantiomer.[27] This differential clearance results in a higher systemic exposure (Area Under the Curve, or AUC) for the active enantiomer, which may partially compensate for the fact that it constitutes only half of the administered racemic dose.[20] Because CYP2D6 is the primary metabolic pathway, genetic variations in this enzyme (e.g., poor metabolizer phenotypes) or co-administration of CYP2D6 inhibitors can significantly alter the drug's pharmacokinetics, leading to increased plasma concentrations and a higher risk of toxicity.[27]

3.2.4 Elimination and Half-Life

Chlorpheniramine and its metabolites are eliminated from the body primarily through renal excretion in the urine.[3] The rate of excretion can be influenced by urinary pH; an acidic urine pH enhances the urinary excretion of the parent drug.[3]

A key and often misunderstood feature of chlorpheniramine is its elimination half-life (t1/2​). Despite a relatively short duration of clinical action, reported to be 4–6 hours, its half-life is remarkably long and variable, ranging from 13.9 to 43.4 hours in healthy adults, with a mean value across studies often cited as 20–28 hours.[1] The half-life tends to be shorter in children and can be significantly prolonged in individuals with renal impairment.[3]

This disparity between the short perceived duration of action and the long elimination half-life creates a significant pharmacokinetic/pharmacodynamic (PK/PD) paradox. A drug with a half-life exceeding 24 hours would typically be dosed once daily. However, chlorpheniramine's dosing recommendations are for every 4–6 hours, based on the return of symptoms.[6] This frequent dosing schedule, dictated by the short clinical effect, combined with the very long half-life, inevitably leads to substantial drug accumulation in the body with repeated use.[25] Simulation studies have estimated that accumulation ratios can range from 4.1 to 9.4 with regular dosing.[25] This accumulation means that the trough concentration of the drug continuously rises over several days of treatment, increasing the likelihood of dose-related adverse effects such as next-day sedation, cognitive impairment, and anticholinergic toxicity. This phenomenon is particularly dangerous in elderly patients, where reduced clearance already predisposes them to higher drug levels. The short duration of action may be due to factors such as rapid receptor desensitization (tachyphylaxis) or rapid redistribution of the drug from the plasma into deep tissue compartments, causing plasma concentrations to fall below the therapeutic threshold long before the drug is actually eliminated from the body.

Table 3.1: Key Pharmacokinetic Parameters of Chlorpheniramine

Parameter	Value	Source(s)
Oral Bioavailability	25–50% (highly variable)	3
Time to Peak Plasma Concentration (Tmax​)	2–6 hours	7
Plasma Protein Binding	~72%	1
Volume of Distribution (Vd​)	2.5–3.2 L/kg (adults)	26
Elimination Half-life (t1/2​)	13.9–43.4 hours (adults)	3
Primary Metabolic Pathway	Hepatic (CYP2D6-mediated N-demethylation)	1
Route of Excretion	Primarily renal (urine)	3

4.0 Clinical Monograph

4.1 Approved and Off-Label Indications

Chlorpheniramine is a versatile agent with a long history of use for a range of conditions, primarily related to allergic responses.

4.1.1 Management of Allergic Conditions

The primary and most well-established indication for chlorpheniramine is the temporary symptomatic relief of conditions mediated by histamine release.[9] It is officially indicated for managing symptoms of seasonal and perennial allergic rhinitis (hay fever), including sneezing, rhinorrhea (runny nose), itchy and watery eyes, and itching of the nose or throat.[6] Its utility extends to other allergic manifestations such as urticaria (hives), angioedema, and pruritus associated with various dermatological conditions.[4] It is also used to control allergic reactions to foods, drugs, insect bites, and stings.[10]

4.1.2 Symptomatic Relief of the Common Cold

Chlorpheniramine is a very common ingredient in over-the-counter (OTC) combination products intended for the symptomatic management of the common cold.[4] In this context, its antihistaminic and anticholinergic properties are leveraged to reduce rhinorrhea and sneezing.[6] It is important to note that it does not treat the underlying viral infection or shorten the duration of the illness; its role is purely palliative.[6]

4.1.3 Off-Label and Veterinary Uses

• Human Off-Label Use: The most recognized off-label use for chlorpheniramine in adults is the prevention and treatment of motion sickness.[32] Its central nervous system effects, including sedation and anticholinergic activity, are thought to contribute to this efficacy.
• Veterinary Use: In veterinary medicine, chlorpheniramine is frequently used in an off-label capacity to treat allergic conditions in small animals, particularly cats and dogs.[4] It is employed for its antipruritic effects in atopic dermatitis and other allergic skin conditions, and occasionally as a mild sedative.[36]
• Investigational Uses: Due to its diverse pharmacological profile, chlorpheniramine has been explored for other potential applications. Its potent serotonin reuptake inhibitor (SRI) activity has led to investigations of its potential as an antidepressant.[5] More recently, research has focused on its potential antiviral properties, with studies exploring its activity against various strains of influenza virus and even SARS-CoV-2, the virus responsible for COVID-19.[3] Other areas of investigation have included its use in asthma and chronic urticaria.[2]

4.2 Contraindications and High-Risk Populations

The use of chlorpheniramine is restricted in several clinical scenarios and patient populations due to an increased risk of serious adverse events.

4.2.1 Absolute Contraindications

Chlorpheniramine should not be used in individuals with:

• Known hypersensitivity to chlorpheniramine or other alkylamine antihistamines.[23]
• An acute asthma attack, as its anticholinergic effects can thicken bronchial secretions and worsen obstruction.[23]
• Narrow-angle glaucoma, as its anticholinergic (mydriatic) effects can increase intraocular pressure.[6]
• Conditions causing urinary retention, such as bladder neck obstruction or symptomatic prostatic hypertrophy, which can be exacerbated by its anticholinergic effects.[23]
• Stenosing peptic ulcer or pyloroduodenal obstruction.[23]
• Concurrent use of monoamine oxidase (MAO) inhibitors or within 14 days of discontinuing such therapy, as MAOIs can prolong and intensify the anticholinergic and sedative effects of chlorpheniramine.[23]
• Premature infants and neonates, due to their increased susceptibility to anticholinergic side effects and respiratory depression.[23]

4.2.2 High-Risk Populations & Precautions

• Pediatric Population: There are significant safety concerns regarding the use of chlorpheniramine in children. The U.S. Food and Drug Administration (FDA) has issued strong warnings that nonprescription cough and cold products containing chlorpheniramine should not be given to children younger than 4 years of age due to the risk of serious and life-threatening side effects, including metabolic acidosis, seizures, and CNS depression.[6] Caution is advised for use in children aged 4 to 11.[6] Additionally, children may experience a paradoxical reaction characterized by hyperexcitability, restlessness, and insomnia instead of sedation.[13]
• Geriatric Population (≥65 years): Older adults are particularly vulnerable to the adverse effects of chlorpheniramine. They exhibit reduced clearance of the drug and are at a significantly higher risk for CNS effects (confusion, sedation, dizziness) and anticholinergic effects (dry mouth, constipation, urinary retention), which can lead to falls and other complications.[6] The American Geriatrics Society Beers Criteria recommends avoiding first-generation antihistamines in this population.[12] Furthermore, long-term, cumulative use of drugs with strong anticholinergic properties, such as chlorpheniramine, has been epidemiologically linked to an increased risk of developing dementia and Alzheimer's disease.[1]
• Patients with Chronic Conditions: Caution should be exercised when administering chlorpheniramine to patients with pre-existing conditions, including chronic respiratory diseases (e.g., emphysema, chronic bronchitis), cardiovascular disease (e.g., hypertension, ischemic heart disease), hyperthyroidism, and impaired renal or hepatic function.[6]
• Pregnancy and Lactation: Chlorpheniramine is classified as FDA Pregnancy Category B, suggesting that animal studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women.[39] Some sources have considered it a preferred antihistamine for use during pregnancy when necessary.[3] However, its use should be limited to situations where the potential benefit justifies the potential risk.[23] Chlorpheniramine is excreted into breast milk and can cause sedation or irritability in a nursing infant. It may also inhibit lactation. Therefore, its use by breastfeeding mothers is generally not recommended.[17]

4.3 Adverse Drug Reactions (ADRs)

The adverse effect profile of chlorpheniramine is extensive and is primarily driven by its effects on the central nervous system and its anticholinergic properties.

4.3.1 Common and Predictable Side Effects

The most frequently encountered side effects are a direct extension of the drug's primary pharmacology:

• CNS Effects: Sedation, ranging from mild drowsiness to deep sleep, is the most common adverse effect.[1] This is often accompanied by dizziness, lassitude, disturbed coordination, and difficulty concentrating.[1]
• Anticholinergic Effects: Dryness of the mouth, nose, and throat is very common.[6] Other effects include blurred vision, constipation, and increased chest congestion due to thickening of bronchial secretions.[1]
• Gastrointestinal Effects: Nausea, vomiting, loss of appetite, and epigastric distress can occur.[1]

4.3.2 Serious Adverse Events and Long-Term Risks

While less frequent, chlorpheniramine can cause serious adverse reactions that require medical attention:

• Serious ADRs: These include cardiovascular effects such as tachycardia, palpitations, and arrhythmias; neurological effects like confusion, hallucinations, tremors, and seizures; and genitourinary effects such as difficulty urinating and urinary retention.[1] Rare but serious events include blood dyscrasias (e.g., hemolytic anemia, thrombocytopenia) and signs of liver problems such as jaundice.[8] A severe allergic reaction (anaphylaxis) to the drug itself is also possible.[44]
• Long-Term Risks: The most significant concern associated with long-term use, particularly in older adults, is the increased risk of cognitive decline and dementia.[1] This risk is attributed to the cumulative anticholinergic burden on the central nervous system over time.

4.4 Drug Interactions

Chlorpheniramine is subject to a large number of clinically significant drug interactions, which can be broadly categorized as pharmacodynamic or pharmacokinetic in nature. There are over 345 known drug interactions, with the majority being of moderate clinical significance.[43]

4.4.1 Pharmacodynamic Interactions

These interactions occur when drugs with similar or opposing pharmacological effects are co-administered.

• CNS Depressants: The most critical interaction is with other CNS depressants. Concomitant use with alcohol, benzodiazepines, opioids, sedatives, tranquilizers, or other sedating antihistamines results in additive CNS depression, leading to profound drowsiness, impaired judgment, and decreased motor skills.[6] This combination significantly increases the risk of accidents and should be strictly avoided.
• Anticholinergic Agents: When taken with other drugs that have anticholinergic properties (e.g., tricyclic antidepressants, some antipsychotics, antiparkinsonian agents), the risk and severity of anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention, confusion) are magnified.[36]
• Monoamine Oxidase Inhibitors (MAOIs): This combination is contraindicated. MAOIs inhibit the metabolism of chlorpheniramine and potentiate its anticholinergic and CNS depressant effects, which can lead to a hypertensive crisis or severe sedation.[23]

4.4.2 Pharmacokinetic Interactions

These interactions involve one drug altering the absorption, distribution, metabolism, or excretion of another.

• CYP2D6 Inhibitors: As chlorpheniramine is a substrate for the CYP2D6 enzyme, potent inhibitors of this enzyme (e.g., quinidine, bupropion, fluoxetine) can decrease its metabolism. This leads to increased plasma concentrations of chlorpheniramine, a prolonged half-life, and a greater risk of toxicity.[27]
• CYP3A4 Inhibitors: Certain potent CYP3A4 inhibitors, such as tucatinib, can also increase chlorpheniramine levels, and co-administration should be avoided where minimal concentration changes could lead to toxicity.[12]
• Phenytoin: Chlorpheniramine can inhibit the metabolism of phenytoin, an anticonvulsant with a narrow therapeutic index. This can lead to elevated phenytoin levels and potential toxicity.[23]

The widespread inclusion of chlorpheniramine in hundreds of OTC combination products presents a substantial public health challenge. A consumer suffering from a cold might purchase a multi-symptom remedy containing acetaminophen, a decongestant, and chlorpheniramine without specifically identifying the antihistamine component.[10] If that same individual later takes an OTC sleep aid (which often contains another first-generation antihistamine like diphenhydramine) or consumes an alcoholic beverage, they are at high risk for an unintentional overdose or a severe drug interaction. This phenomenon of "therapeutic duplication" and unintended polypharmacy is difficult for consumers to navigate due to the bewildering array of brand names and formulations. It underscores the critical need for patient education and pharmacist counseling to prevent accidental harm from these readily available legacy medications.

5.0 Dosage, Administration, and Pharmaceutical Formulations

5.1 Recommended Dosage Regimens

The dosage of chlorpheniramine must be carefully tailored based on the patient's age and the specific formulation being used (immediate-release vs. extended-release). All dosage forms are administered orally.[1]

5.1.1 Adult Dosing (and Children ≥12 years)

• Immediate-Release Formulations (e.g., 4 mg tablets; 2 mg/5 mL liquid): The standard dose is 4 mg taken every 4 to 6 hours as needed. The maximum recommended dose in a 24-hour period is 24 mg.[13]
• Extended-Release Formulations (e.g., 8 mg or 12 mg tablets): The typical dose is one 8 mg or 12 mg tablet taken every 12 hours (twice daily). The maximum recommended dose in a 24-hour period is 24 mg.[6] These formulations should be swallowed whole and not crushed or chewed to maintain their long-acting properties.[13]

5.1.2 Pediatric Dosing and Associated Precautions

Dosing in children requires extreme caution and adherence to age- and weight-based guidelines.

• Children 6 to <12 years: For immediate-release products, the dose is 2 mg (e.g., one-half of a 4 mg tablet or 5 mL of a 2 mg/5 mL liquid) every 4 to 6 hours. The maximum daily dose should not exceed 12 mg.[13]
• Children 2 to <6 years: Use in this age group should only be under the direction and supervision of a clinician. A typical dose is 1 mg every 4 to 6 hours, with a maximum daily dose of 6 mg.[26]
• Children <2 years: Use is not recommended and is contraindicated in neonates. Regulatory agencies like the FDA have issued strong public health advisories against the use of OTC cough and cold preparations containing chlorpheniramine in this age group due to the risk of severe adverse events and lack of proven benefit.[6]

Table 5.1: Dosage and Administration Summary for Chlorpheniramine Maleate

Age Group	Formulation Type	Recommended Dose	Frequency	Maximum 24-Hour Dose
Adults & Children ≥12 years	Immediate-Release	4 mg	Every 4–6 hours	24 mg
	Extended-Release	8 mg or 12 mg	Every 12 hours	24 mg
Children 6 to <12 years	Immediate-Release	2 mg	Every 4–6 hours	12 mg
Children 2 to <6 years	Immediate-Release	1 mg (Clinician supervision required)	Every 4–6 hours	6 mg
Children <2 years	All Formulations	Not Recommended / Contraindicated	-	-

5.2 Available Formulations

Chlorpheniramine is available in a vast array of formulations, both as a single active ingredient and, more commonly, as part of multi-ingredient products.

5.2.1 Single-Agent Preparations

Chlorpheniramine maleate is marketed as a standalone product in several forms to suit different patient needs:

• Oral Tablets: Most commonly available as 4 mg immediate-release tablets.[6]
• Extended-Release Tablets/Capsules: Available in 8 mg and 12 mg strengths for twice-daily dosing.[6]
• Oral Liquid/Syrup: Typically formulated at a concentration of 2 mg/5 mL, which is useful for pediatric patients or adults who have difficulty swallowing pills.[6]
• Chewable Tablets: Also available for ease of administration in certain populations.[6]
• Injectable Formulations: While less common in routine practice, intravenous (IV), intramuscular (IM), and subcutaneous (SubQ) formulations have been documented for use in more acute clinical settings.[3]

Common brand names for single-agent products include Chlor-Trimeton, Piriton (UK), Aller-Chlor, and Teldrin.[6]

5.2.2 Common Combination Products

The majority of chlorpheniramine use occurs through combination products designed to treat multiple symptoms of allergies, colds, and flu. These formulations are a dominant feature of the OTC market. Chlorpheniramine is frequently combined with one or more of the following classes of drugs:

• Analgesics/Antipyretics: Primarily acetaminophen, but also aspirin or ibuprofen.[4]
• Decongestants: Phenylephrine and pseudoephedrine are the most common partners.[10] Phenylpropanolamine was historically used but was withdrawn from the U.S. market due to an increased risk of hemorrhagic stroke.[1]
• Antitussives (Cough Suppressants): Dextromethorphan is the most common OTC partner. Prescription combinations may include opioid antitussives like codeine or hydrocodone.[1]
• Expectorants: Guaifenesin is sometimes included to help loosen phlegm.[10]
• Other Antihistamines/Anticholinergics: Some formulations may contain other antihistamines (e.g., pheniramine, pyrilamine) or anticholinergic agents (e.g., methscopolamine).[10]

The complexity of these products can be extensive, with some formulations containing four, five, or even more active ingredients.[10] This vast array of products, sold under countless brand names like Coricidin, Tylenol Cold, Alka-Seltzer Plus, and Triaminic, contributes to the risk of unintentional overdose and drug interactions as previously discussed.[10]

6.0 Historical Context and Global Regulatory Status

6.1 Discovery, Development, and Introduction to Clinical Practice

Chlorpheniramine emerged from the first wave of antihistamine research that began in the late 1930s, following the discovery of histamine's central role in allergic and anaphylactic reactions.[58] As a synthetic alkylamine derivative, it represented an advancement over earlier, more toxic compounds. The drug was patented in 1948 and entered clinical practice in 1949, with some sources citing its introduction to medicine in 1951.[1] It quickly became one of the most potent and widely used of the classical, first-generation antihistamines, a position it has maintained for over 70 years due to its established efficacy, rapid onset of action, and low cost.[1] Its introduction provided clinicians with an effective tool to manage the debilitating symptoms of hay fever, hives, and other common allergic conditions.[58]

6.2 Regulatory Approvals and Market Status

Despite its age, chlorpheniramine remains a globally recognized and regulated pharmaceutical agent, with its status reflecting an evolving understanding of its risk-benefit profile.

6.2.1 United States (FDA)

In the United States, chlorpheniramine has been approved for decades and is widely available as a generic drug and in numerous OTC products.[1] Its long-standing presence predates many modern regulatory frameworks, but it continues to be the subject of FDA oversight. The agency has approved new combination products containing chlorpheniramine well into the 21st century, such as Zutripro (with hydrocodone and pseudoephedrine) in 2011, Advil Allergy & Congestion Relief (with ibuprofen and phenylephrine) in 2011, and Tuxarin ER (with codeine) in 2015.[56] These approvals often follow the 505(b)(2) regulatory pathway, which allows manufacturers to rely in part on the FDA's previous findings of safety and effectiveness for a listed drug.[61] The FDA has also published specific bioequivalence guidance for the development of generic extended-release chlorpheniramine tablets.[62] Concurrently, the agency has taken a much stricter stance on its use in vulnerable populations, issuing strong warnings against the use of OTC cough and cold products containing chlorpheniramine in children under 4 years of age.[6]

6.2.2 Europe (EMA/MHRA)

In Europe, where the drug is known as chlorphenamine, it is authorized at the national level by individual member state agencies. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved it for treating allergic symptoms, with products like Piriton and Allerief being common brands.[33] The European Medicines Agency (EMA) is involved in pharmacovigilance, conducting Periodic Safety Update Single Assessments (PSUSA) for combination products containing chlorphenamine to ensure their ongoing safety profile remains acceptable.[65]

6.2.3 Australia (TGA)

The Therapeutic Goods Administration (TGA) in Australia also authorizes the use of chlorphenamine, where it is commonly found in combination products for cold, flu, and sinus relief, such as APOHEALTH and Chemists' Own brands.[66] Similar to the FDA, the TGA has issued specific and stern safety warnings regarding the use of first-generation antihistamines in children. The TGA advises against their use for cough and cold symptoms in children under 6 years of age and prohibits their use for any reason in children under 2 years.[70]

The regulatory history of chlorpheniramine provides a compelling case study of how a legacy drug is viewed through the lens of modern pharmacovigilance. A medication that has been on the market for over 70 years might be perceived as having a static and fully understood safety profile. However, the continuous stream of new combination product approvals, updated safety warnings, and ongoing reviews by global agencies demonstrates a dynamic regulatory lifecycle. This evolution is driven by two primary forces: pharmaceutical innovation in creating new formulations (e.g., extended-release) and combinations, and a deeper, data-driven understanding of drug risks in specific populations. The increasingly stringent restrictions on pediatric use by both the FDA and TGA are a clear example of this shift. A practice that was once commonplace—giving sedating antihistamines to young children for colds—is now strongly discouraged based on accumulated evidence of potential harm and a lack of proven efficacy. This illustrates that even the most established OTC drugs are not immune to evolving standards of care and that their risk-benefit assessment is a continuous, rather than a one-time, process.

7.0 Conclusion and Expert Insights

7.1 Synthesis of Chlorpheniramine's Therapeutic Profile

Chlorpheniramine stands as a paradigm of a mid-20th-century pharmaceutical success story: a potent, effective, and versatile agent that has provided symptomatic relief to millions of patients for generations. Its primary value lies in its rapid and reliable antagonism of the histamine H1 receptor, making it a cornerstone therapy for acute allergic symptoms. However, a comprehensive analysis reveals a far more complex profile. Its classification as a "dirty drug" is well-earned, with significant off-target activities at muscarinic and serotonergic sites that define both its utility in some contexts and its extensive adverse effect profile. The drug's identity is further complicated by its racemic nature, where only one of its two enantiomers provides the desired therapeutic effect, and by its paradoxical pharmacokinetics, which promote drug accumulation and increase the risk of toxicity with standard dosing regimens.

7.2 Modern Clinical Placement and Future Perspectives

In the landscape of modern medicine, chlorpheniramine's position has shifted. The development of second- and third-generation non-sedating antihistamines has relegated chlorpheniramine from a first-line agent to a secondary option for many allergic conditions, particularly where daytime alertness is critical. Nevertheless, it remains highly relevant due to its low cost, proven potency, and ubiquitous presence in the OTC market for multi-symptom cold and allergy relief.

This continued prevalence necessitates a high degree of clinical vigilance. The drug's PK/PD paradox—a short duration of action coupled with a long elimination half-life—is a critical concept that must be communicated to patients to avoid the risks associated with accumulation. The significant safety concerns in geriatric populations, especially the link to cognitive impairment and dementia, and the strong contraindications in young children, demand that healthcare providers actively counsel against its inappropriate use. Perhaps the greatest modern challenge posed by chlorpheniramine is the risk of therapeutic misadventure arising from its inclusion in countless combination products. This creates a confusing landscape for consumers and elevates the potential for unintentional overdose and drug interactions.

While future research may continue to probe its potential for repurposing as an antiviral or other agent, its primary clinical role is unlikely to change. Chlorpheniramine will persist as a legacy drug—an effective but blunt instrument from a previous era of pharmacology. Its continued safe use hinges not on new discoveries, but on a renewed appreciation among clinicians and patients alike that its benefits must be constantly and carefully weighed against a well-defined and significant profile of risks.

Works cited

1. Chlorphenamine - Wikipedia, accessed September 26, 2025, https://en.wikipedia.org/wiki/Chlorphenamine
2. Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature | Bentham Science, accessed September 26, 2025, https://benthamscience.com/public/article/124120
3. Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature - ResearchGate, accessed September 26, 2025, https://www.researchgate.net/publication/361067649_Chlorpheniramine_an_Old_Drug_with_New_Potential_Clinical_Applications_A_Comprehensive_Review_of_the_Literature
4. Chlorpheniramine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 26, 2025, https://go.drugbank.com/drugs/DB01114
5. (+-)-Chlorpheniramine | C16H19ClN2 | CID 2725 - PubChem, accessed September 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Chlorpheniramine
6. Chlorpheniramine: MedlinePlus Drug Information, accessed September 26, 2025, https://medlineplus.gov/druginfo/meds/a682543.html
7. What is the mechanism of Chlorpheniramine Maleate? - Patsnap Synapse, accessed September 26, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-chlorpheniramine-maleate
8. Chlorpheniramine: Generic, Cold & Allergy Uses, Warnings, Side Effects, Dosage, accessed September 26, 2025, https://www.medicinenet.com/chlorpheniramine/article.htm
9. Chlorpheniramine Tablets: Package Insert / Prescribing Info - Drugs.com, accessed September 26, 2025, https://www.drugs.com/pro/chlorpheniramine-tablets.html
10. Chlorpheniramine - brand name list from Drugs.com, accessed September 26, 2025, https://www.drugs.com/ingredient/chlorpheniramine.html
11. chlorpheniramine - ClinPGx, accessed September 26, 2025, https://www.clinpgx.org/chemical/PA448960
12. Indication-specific dosing for ChlorTrimeton, Diabetic Tussin (chlorpheniramine), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. - Medscape Reference, accessed September 26, 2025, https://reference.medscape.com/drug/chlortrimeton-chlorpheniramine-343386
13. Chlorpheniramine: How Does It Work? - Nursing Center, accessed September 26, 2025, https://www.nursingcenter.com/ncblog/april-2023/chlorpheniramine
14. pubchem.ncbi.nlm.nih.gov, accessed September 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Chlorpheniramine#:~:text=It%20is%20a%20tertiary%20amino,and%20a%20member%20of%20pyridines.&text=A%20histamine%20H1%20antagonist%20used,been%20used%20in%20veterinary%20applications.
15. Chlorpheniramine Maleate | CAS#113-92-8 | CAS#132-22-9 | H1-Receptor Antagonist, accessed September 26, 2025, https://www.medkoo.com/products/7415
16. Chlorphenamine maleate | 113-92-8 - ChemicalBook, accessed September 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9142008.htm
17. Chlorpheniramine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501530/
18. Chlorpheniramine | CAS No- 132-22-9 | Simson Pharma Limited, accessed September 26, 2025, https://www.simsonpharma.com/us/product/chlorpheniramine
19. Chlorpheniramine Maleate - LKT Labs, accessed September 26, 2025, https://lktlabs.com/product/chlorpheniramine-maleate/
20. Intestinal absorption and metabolism of chlorpheniramine enantiomers in rat | Request PDF, accessed September 26, 2025, https://www.researchgate.net/publication/229441098_Intestinal_absorption_and_metabolism_of_chlorpheniramine_enantiomers_in_rat
21. CHLORPHENIRAMINE MALEATE | CAMEO Chemicals | NOAA, accessed September 26, 2025, https://cameochemicals.noaa.gov/chemical/20026
22. Chlorpheniramine maleate (Chlorphenamine maleate) | Histamine H1 Receptor Antagonist | MedChemExpress, accessed September 26, 2025, https://www.medchemexpress.com/Chlorpheniramine-maleate.html
23. Uses of Allermine 4mg - Vinmec, accessed September 26, 2025, https://www.vinmec.com/eng/blog/uses-of-allermine-4mg-en
24. Evaluation of the bioequivalence of two formulations containing the combination of 400 mg of acetaminophen - SciELO, accessed September 26, 2025, https://www.scielo.br/j/bjps/a/QWCvNtZcbxn66mkrpkTXx4w/?lang=en&format=pdf
25. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults - PubMed, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/7106172/
26. Chlorpheniramine: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed September 26, 2025, https://www.medcentral.com/drugs/monograph/4156-382543/chlorpheniramine-oral
27. The Roles of CYP2D6 and Stereoselectivity in the Clinical Pharmacokinetics of Chlorpheniramine - PubMed, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/11994058/
28. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults | Semantic Scholar, accessed September 26, 2025, https://www.semanticscholar.org/paper/Pharmacokinetics-of-chlorpheniramine-after-and-oral-Huang-Athanikar/615cb60ecc8bae5d1fa0d1b19010d12cf0fa45da
29. Clinical Pharmacokinetics of Chlorpheniramine | Semantic Scholar, accessed September 26, 2025, https://www.semanticscholar.org/paper/Clinical-Pharmacokinetics-of-Chlorpheniramine-Rumore/6febe32b0b01f2123222effd1209b37ad4cb0fec
30. Chlorpheniramine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 26, 2025, https://www.drugs.com/dosage/chlorpheniramine.html
31. (PDF) Chlorpheniramine plasma concentration and histamine H1-receptor occupancy*, accessed September 26, 2025, https://www.researchgate.net/publication/232794187_Chlorpheniramine_plasma_concentration_and_histamine_H1-receptor_occupancy
32. Chlorpheniramine: Drug information, accessed September 26, 2025, http://maadi-clinical.byethost8.com/d/topic.htm?path=chlorpheniramine-drug-information
33. About chlorphenamine - NHS, accessed September 26, 2025, https://www.nhs.uk/medicines/chlorphenamine-including-piriton/about-chlorphenamine/
34. Chlorpheniramine Maleate: Allergy & Cold Uses, Side Effects, accessed September 26, 2025, https://www.emedicinehealth.com/what_is_chlorpheniramine_maleate_used_for/article_em.htm
35. www.emedicinehealth.com, accessed September 26, 2025, https://www.emedicinehealth.com/what_is_chlorpheniramine_maleate_used_for/article_em.htm#:~:text=Chlorpheniramine%20maleate%20is%20also%20used,treat%20motion%20sickness%20in%20adults.
36. Chloropheniramine | 132-22-9 - ChemicalBook, accessed September 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32130382.htm
37. Chlorpheniramine Maleate | VCA Animal Hospitals, accessed September 26, 2025, https://vcahospitals.com/know-your-pet/chlorpheniramine-maleate
38. Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature - PubMed, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/35652393/
39. Chlorpheniramine Uses, Side Effects & Warnings - Drugs.com, accessed September 26, 2025, https://www.drugs.com/mtm/chlorpheniramine.html
40. Chlorpheniramine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 26, 2025, https://www.rxlist.com/chlorpheniramine/generic-drug.htm
41. Who can and cannot take chlorphenamine - NHS, accessed September 26, 2025, https://www.nhs.uk/medicines/chlorphenamine-including-piriton/who-can-and-cannot-take-chlorphenamine/
42. What is Chlorpheniramine Maleate used for? - Patsnap Synapse, accessed September 26, 2025, https://synapse.patsnap.com/article/what-is-chlorpheniramine-maleate-used-for
43. Chlorpheniramine Interactions - Drugs.com, accessed September 26, 2025, https://www.drugs.com/drug-interactions/chlorpheniramine.html
44. Side effects of chlorphenamine - NHS, accessed September 26, 2025, https://www.nhs.uk/medicines/chlorphenamine-including-piriton/side-effects-of-chlorphenamine/
45. Chlo-Amine Interactions Checker - Drugs.com, accessed September 26, 2025, https://www.drugs.com/drug-interactions/chlorpheniramine,chlo-amine.html
46. Chlorpheniramine and Alcohol/Food Interactions - Drugs.com, accessed September 26, 2025, https://www.drugs.com/food-interactions/chlorpheniramine.html
47. How and when to take chlorphenamine - NHS, accessed September 26, 2025, https://www.nhs.uk/medicines/chlorphenamine-including-piriton/how-and-when-to-take-chlorphenamine/
48. Label: CHLORPHENIRAMINE MALEATE 4MG tablet, coated - DailyMed, accessed September 26, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d974959-25fc-4707-9b72-9afbf47b76f1
49. Label: ED CHLORPED JR- chlorpheniramine maleate liquid - DailyMed, accessed September 26, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a5e5968-1930-465a-9b8c-45ed936a0e11
50. 9 Antihistamines for the treatment of Allergic Rhinitis in Children - Pediatric Pharmacotherapy - The University of Virginia, accessed September 26, 2025, https://med.virginia.edu/pediatrics/wp-content/uploads/sites/237/2015/12/199509.pdf
51. Chlorphenamine maleate for allergy - Medicines For Children, accessed September 26, 2025, https://www.medicinesforchildren.org.uk/medicines/chlorphenamine-maleate-for-allergy/
52. www.ncbi.nlm.nih.gov, accessed September 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK582633/#:~:text=Chlorpheniramine%20is%20sold%20under%20different,%2C%20Polaramine%C2%AE%2C%20Teldrin%C2%AE.
53. Chlorpheniramine tablets - Cleveland Clinic, accessed September 26, 2025, https://my.clevelandclinic.org/health/drugs/18741-chlorpheniramine-tablets
54. Chlorpheniramine, Dexchlorpheniramine Monograph for Professionals - Drugs.com, accessed September 26, 2025, https://www.drugs.com/monograph/chlorpheniramine-dexchlorpheniramine.html
55. Chlorpheniramine/phenylephrine: Uses, Side Effects, Dosage & Reviews - GoodRx, accessed September 26, 2025, https://www.goodrx.com/nohist-lq/what-is
56. Zutripro (chlorpheniramine, hydrocodone and pseudoephedrine) FDA Approval History, accessed September 26, 2025, https://www.drugs.com/history/zutripro.html
57. Tuxarin ER (chlorpheniramine and codeine) FDA Approval History - Drugs.com, accessed September 26, 2025, https://www.drugs.com/history/tuxarin-er.html
58. Chlorpheniramine | Antihistamine, Allergy Relief, Decongestant | Britannica, accessed September 26, 2025, https://www.britannica.com/technology/chlorpheniramine
59. Histamine pharmacology: from Sir Henry Dale to the 21st century - PMC - PubMed Central, accessed September 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7012941/
60. 022113Orig1s000 - accessdata.fda.gov, accessed September 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022113Orig1s000MedR.pdf
61. 207768Orig1s000 - accessdata.fda.gov, accessed September 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207768Orig1s000CrossR.pdf
62. Chlorpheniramine maleate Oral Extended Release Tablet - accessdata.fda.gov, accessed September 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_007638.pdf
63. Public Assessment Report National Procedure Chlorphenamine Maleate 2 mg/5 ml Oral Solution (chlorphenamine maleate) PL 20416/ - NET, accessed September 26, 2025, https://mhraproducts4853.blob.core.windows.net/docs/cfa007333b756fa9494ec7e78a1babbc08ad341a
64. Chlorphenamine (Piriton) - drowsy (sedating) antihistamine - NHS, accessed September 26, 2025, https://www.nhs.uk/medicines/chlorphenamine-including-piriton/
65. PSUSA/00000699/202411 - periodic safety update report single assessment, accessed September 26, 2025, https://www.ema.europa.eu/en/medicines/psusa/psusa-00000699-202411
66. APOHEALTH COLD RELIEF - Consumer Medicine Information (CMI) summary, accessed September 26, 2025, https://www.nps.org.au/assets/medicines/c3517336-c207-4ff1-a307-a66500ba4801.pdf
67. Chlorphenamine + phenylephrine - Healthdirect, accessed September 26, 2025, https://www.healthdirect.gov.au/medicines/medicinal-product/aht,23239/chlorphenamine-+-phenylephrine
68. Chemists' Own® Sinus + Allergy & Pain Relief, accessed September 26, 2025, https://www.chemistsown.com.au/product/chemists-own-sinus-allergy-pain-relief-pe-tablets-24/
69. CHEMISTS' OWN Day + Night Cold & Flu Relief tablets, accessed September 26, 2025, https://www.nps.org.au/assets/medicines/7eb4157c-6583-4514-9e30-ae6100aafa89.pdf
70. Active ingredient: paracetamol + pseudoephedrine + chlorphenamine - Healthdirect, accessed September 26, 2025, https://www.healthdirect.gov.au/medicines/medicinal-product/aht,23505/paracetamol-+-pseudoephedrine-+-chlorphenamine